Cargando…
Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals
Myasthenia gravis (MG) is a chronic, fluctuating, antibody-mediated autoimmune disorder directed against the post-synaptic neuromuscular junctions of skeletal muscles, resulting in a wide spectrum of manifestations ranging from mild to potentially fatal. Given its unique natural course, designing an...
Autores principales: | Menon, Deepak, Bril, Vera |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152838/ https://www.ncbi.nlm.nih.gov/pubmed/35639288 http://dx.doi.org/10.1007/s40265-022-01726-y |
Ejemplares similares
-
Novel Treatments in Myasthenia Gravis
por: Menon, Deepak, et al.
Publicado: (2020) -
Psychometric Properties of the Quantitative Myasthenia Gravis Score and the Myasthenia Gravis Composite Scale
por: Barnett, Carolina, et al.
Publicado: (2015) -
FcRN receptor antagonists in the management of myasthenia gravis
por: Bhandari, Vinaya, et al.
Publicado: (2023) -
Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis
por: Hewett, Karen, et al.
Publicado: (2018) -
Development and validation of the Myasthenia Gravis Impairment Index
por: Barnett, Carolina, et al.
Publicado: (2016)